Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT03896152
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
13
Enrollment
INDUSTRY
Sponsor class
Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG:
LNP023
Sponsor
Novartis Pharmaceuticals